Literature DB >> 33139285

Emergence of Resistance in Klebsiella aerogenes to Piperacillin-Tazobactam and Ceftriaxone.

Marco M Custodio1, Daniel Sanchez2, Beverly Anderson2, Keenan L Ryan1, Carla Walraven1, Renee-Claude Mercier3.   

Abstract

We examined the effects of piperacillin-tazobactam (TZP) concentration and bacterial inoculum on in vitro killing and the emergence of resistance in Klebsiella aerogenes The MICs for 15 clinical respiratory isolates were determined by broth microdilution for TZP and by Etest for ceftriaxone (CRO) and cefepime (FEP). The presence of resistance in TZP-susceptible isolates (n = 10) was determined by serial passes over increasing concentrations of TZP-containing and CRO-containing agar plates. Isolates with growth on TZP 16/4-μg/ml and CRO 8-μg/ml plates (n = 5) were tested in high-inoculum (HI; 7.0 log10 CFU/ml) and low-inoculum (LI; 5.0 log10 CFU/ml) time-kill studies. Antibiotic concentrations were selected to approximate TZP 3.375 g every 8 h (q8h) via a 4-h prolonged-infusion free peak concentration (40 μg/ml [TZP40]), peak epithelial lining fluid (ELF) concentrations, and average AUC0-24 values for TZP (20 μg/ml [TZP20] and 10 μg/ml [TZP10], respectively), the ELF FEP concentration (14 μg/ml), and the average AUC0-24 CRO concentration (6 μg/ml). For HI, FEP exposure significantly reduced 24-h inocula against all comparators (P ≤ 0.05) with a reduction of 4.93 ± 0.64 log10 CFU/ml. Exposure to TZP40, TZP20, and TZP10 reduced inocula by 0.81 ± 0.43, 0.21 ± 0.18, and 0.05 ± 0.16 log10 CFU/ml, respectively. CRO-exposed isolates demonstrated an increase of 0.42 ± 0.39 log10 CFU/ml compared to the starting inocula, with four of five CRO-exposed isolates demonstrating TZP-nonsusceptibility. At LI after 24 h of exposure to TZP20 and TZP10, the starting inoculum decreased by averages of 2.24 ± 1.98 and 2.91 ± 0.50 log10 CFU/ml, respectively. TZP demonstrated significant inoculum-dependent killing, warranting dose optimization studies.
Copyright © 2021 American Society for Microbiology.

Entities:  

Keywords:  AmpC; AmpC derepression; Klebsiella aerogeneszzm321990; ceftriaxone; piperacillin-tazobactam

Mesh:

Substances:

Year:  2021        PMID: 33139285      PMCID: PMC7848979          DOI: 10.1128/AAC.01038-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  ampR gene mutations that greatly increase class C beta-lactamase activity in Enterobacter cloacae.

Authors:  A Kuga; R Okamoto; M Inoue
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

Review 2.  Diagnosis and treatment of ventilator-associated pneumonia: fiberoptic bronchoscopy with bronchoalveolar lavage is essential.

Authors:  Jean-Yves Fagon
Journal:  Semin Respir Crit Care Med       Date:  2006-02       Impact factor: 3.119

3.  Clinical comparison of ertapenem and cefepime for treatment of infections caused by AmpC beta-lactamase-producing Enterobacteriaceae.

Authors:  Lisa M Blanchette; Joseph L Kuti; David P Nicolau; Michael D Nailor
Journal:  Scand J Infect Dis       Date:  2014-09-29

4.  Species-specific mutation rates for ampC derepression in Enterobacterales with chromosomally encoded inducible AmpC β-lactamase.

Authors:  Rebekka Kohlmann; Tobias Bähr; Sören G Gatermann
Journal:  J Antimicrob Chemother       Date:  2018-06-01       Impact factor: 5.790

5.  Mechanism of suppression of piperacillin resistance in enterobacteria by tazobactam.

Authors:  T A Kadima; J H Weiner
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

Review 6.  AmpC beta-lactamases.

Authors:  George A Jacoby
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

7.  Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.

Authors:  Lorna E T Stearne; Wil H F Goessens; Johan W Mouton; Inge C Gyssens
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

8.  Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections.

Authors:  T W Felton; W W Hope; B M Lomaestro; J M Butterfield; A L Kwa; G L Drusano; T P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2012-05-14       Impact factor: 5.191

9.  Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC beta-lactamase: implications for antibiotic use.

Authors:  Sang-Ho Choi; Jung Eun Lee; Su Jin Park; Seong-Ho Choi; Sang-Oh Lee; Jin-Yong Jeong; Mi-Na Kim; Jun Hee Woo; Yang Soo Kim
Journal:  Antimicrob Agents Chemother       Date:  2007-12-17       Impact factor: 5.191

10.  Impact of Bolus dosing versus continuous infusion of Piperacillin and Tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa.

Authors:  T W Felton; J Goodwin; L O'Connor; A Sharp; L Gregson; J Livermore; S J Howard; M N Neely; W W Hope
Journal:  Antimicrob Agents Chemother       Date:  2013-09-03       Impact factor: 5.191

View more
  1 in total

1.  Activity of meropenem/vaborbactam and comparators against non-carbapenemase-producing carbapenem-resistant Enterobacterales isolates from Europe.

Authors:  Dee Shortridge; Lalitagauri M Deshpande; Jennifer M Streit; Mariana Castanheira
Journal:  JAC Antimicrob Resist       Date:  2022-09-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.